Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Punnoose

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 25, 2012
Challenges and opportunities in the use of CTCs for companion diagnostic developmentElizabeth A Punnoose, Mark R Lackner
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosisNicholas Dompe, Celina Sanchez Rivers, Li Li, et al.
Plos One|September 15, 2010
Molecular biomarker analyses using circulating tumor cellsElizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2012
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinibElizabeth A Punnoose, Siminder Atwal, Weiqun Liu, et al.
Blood Advances|January 4, 2018
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsetsChristopher R Bolen, Ronald McCord, Sarah Huet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2010
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsCarol O'Brien, Jeffrey J Wallin, Deepak Sampath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III StudyArnon P Kater, John F Seymour, Peter Hillmen, et al.
Nature Medicine|September 4, 2007
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILKlaus W Wagner, Elizabeth A Punnoose, Thomas Januario, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
The New England Journal of Medicine|March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 25, 2012
Challenges and opportunities in the use of CTCs for companion diagnostic developmentElizabeth A Punnoose, Mark R Lackner
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosisNicholas Dompe, Celina Sanchez Rivers, Li Li, et al.
Plos One|September 15, 2010
Molecular biomarker analyses using circulating tumor cellsElizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2012
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinibElizabeth A Punnoose, Siminder Atwal, Weiqun Liu, et al.
Blood Advances|January 4, 2018
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsetsChristopher R Bolen, Ronald McCord, Sarah Huet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2010
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsCarol O'Brien, Jeffrey J Wallin, Deepak Sampath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III StudyArnon P Kater, John F Seymour, Peter Hillmen, et al.
Nature Medicine|September 4, 2007
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILKlaus W Wagner, Elizabeth A Punnoose, Thomas Januario, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
The New England Journal of Medicine|March 22, 2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F Seymour, Thomas J Kipps, Barbara Eichhorst, et al.
Pageof 2